Top Links

Articles Related to tablet

Randomised, 2-Sequence, 4-Period Replicate Cross-Over Bioequivalence Study of A New Riluzole Orodispersible Film Vs. A Reference Tablet in Healthy Volunteers

Purpose: The present bioequivalence study aimed at demonstrating the bioequivalence of a recently developed novel riluzole orodispersible film vs. a reference tablet. Methods: Healthy male and female volunteers received single oral doses of 50 mg of riluzole, as test and reference formulation, under fasting conditions, in each of 4 subsequent periods separated by wash-out intervals of at least 7 days, according to a 2-treatment, 4-period, replicate randomised cross-over design. Findings: Riluzole plasma concentrations were almost superimposable. Riluzole attained a similar peak concentration (315.62±124.95 ng/mL with the film and 278.81±123.32 ng/mL with the tablet) at a median tmax of 0.75 h after both treatments. Then, riluzole plasma concentrations showed a superimposable decline from the peak up to 36 h post-dose, with mean half-lives of 10.22±1.66 and 10.22±1.48 h with the film and the tablet. Mean AUC0-t was 1263.40±571.58 h*ng/mL with the film and 1135.98±514.98 h*ng/mL with the tablet. The 90% confidence intervals of Cmax, AUC0-t and AUC0-¥ of riluzole fell within the predefined range 80.00-125.00%. The treatments did not differ significantly either in tmax or t1/2. On average, the test orodispersible film dissolved on the tongue in a median time of about 2.5 min with a range of 0.7-5.7 min. Orodispersible film palatability was good or acceptable for most subjects.
View complete article: PDF  |  Full-text

Stability Indicating Method Development and Validation for the Determination of Armodafinil in Pharmaceutical Tablet Dosage Form by RP-HPLC

The present research deals with the development of a stability indicating reverse phase HPLC with PDA detector method for the determination of Armodafinil Agilent XDB-C18, 150×4.6mm, 5µm or Equivalent column. The present research deals with the development of a stability indicating reverse phase HPLC with PDA detector method for the determination of Armodafinil Agilent XDB-C18,
View complete article: PDF  |  Full-text

Bioequivalence Study of Donepezil 10 mg Orally Disintegrating Tablets in Healthy Thai Volunteers Under Fasting Conditions

Donepezil is a potent, selective, noncompetitive and reversible inhibitor of acetylcholinesterase, commonly used for the treatment of Alzheimer’s disease. The form of orally disintegrating tablets (ODTs) is a good alternative dosage form for patients who have a difficulty in swallowing conventional tablets or capsules.
View complete article: PDF  |  Full-text

Comparative Bioequivalence Studies of Pantoprazole 40 mg Delayed-Release Tablet Formulations in Healthy Thai Volunteers

Pantoprazole is a H+,K+-ATPase enzyme inhibitor for the treatment of acid-related gastrointestinal diseases. The Government Pharmaceutical Organization (GPO), Thailand had developed Pantoprazole GPO® (pantoprazole 40 mg delayed-release tablets) as a generic substitute for the corresponding innovator product, CONTROLOC® 40 mg.
View complete article: PDF  |  Full-text

Bioequivalence of Two Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600/200/300 mg Fixed-Dose Combination Tablets in Healthy Thai Male Volunteers under Fasting Conditions

Fixed-dose combination tablet formulation of efavirenz/emtricitabine/tenofovir disoproxil fumarate 600/200/300 mg is an antiretroviral therapy comprising one non-nucleoside reverse-transcriptase inhibitor and two nucleoside reverse-transcriptase inhibitors to control human immunodeficiency virus infection.
View complete article: PDF  |  Full-text

Bioequivalence Evaluation of Two Clopidogrel Immediate Release Tablet Formulations in Healthy Thai Volunteers Under Fasting Conditions

Clopidogrel is used for acute coronary syndrome and prevention of atherothrombotic events. To improve clinical outcomes, patient adherence to treatment is necessary. However, continuous use of branded product may cause economic burden to patients and healthcare system. The Government Pharmaceutical Organization (GPO), Thailand had developed a generic product of clopidogrel to reduce cost of treatment and improve accessibility to medicines for Thai people.
View complete article: PDF  |  Full-text

Bioequivalence between Two Tablets of Levetiracetam in Healthy Subjects under Fasting Condition

Bioavailability of two formulations containing levetiracetam 750 mg film-coated tablets was compared in a fasting bioequivalence study. The study was single dose, randomized, open label, and two-period crossover, with Brazilian healthy subjects, males and nonpregnant females. Blood samples were taken for 36 hours after drug administration and plasmatic concentrations were determined using a validated HPLC-MS/MS method. Confidence intervals (CI90%) for the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC0-t) were determined by calculating LN-transformed data. The ratios and 90% CI for the geometric mean test/reference were 97.41% (91.45- 103.75%) for Cmax and 99.77% (97.07- 102.54%) for AUC0-t.
View complete article: PDF  |  Full-text

Bioequivalence Study of Olanzapine 5 mg Orally Disintegrating Tablet Formulations in Healthy Thai Volunteers under Fasting Conditions

A comparative randomized, single dose, two-way crossover, open label study was carried out to assess bioequivalence and tolerability of test (ZOLAN GPO®) and reference (Zyprexa Zydis®) products of olanzapine 5 mg orally disintegrating tablets for interchange ability in the same quality and safety.
View complete article: PDF  |  Full-text

A Bioequivalence Study of Two Formulations of Rosuvastatin

Aim of this study was to compare the bioavailability of two tablet formulations containing Rosuvastatin: Rosuvastatin tablets 40 mg manufactured by MacLeods Pharmaceuticals Ltd. (marketed in Italy with the brand name Exorta®) and CRESTOR® 40 mg tablets marketed by Astra Zeneca.
View complete article: PDF  |  Full-text

A Bioequivalence Study of Two Formulations of Levetiracetam

This study was conducted to compare the bioavailability of 1000 mg levetiracetam film-coated tablet, marketed in Italy as Italept®, with Keppra® coated tablet.
View complete article: PDF  |  Full-text

Bioequivalence between two extended Release Tablets of Oxycodone Hydrochloride in Healthy Subjects under Fasting and Fed Conditions

Bioavailability of different formulations of oxycodone 20 mg extended release tablets was compared in two bioequivalence studies, one under fasting conditions and the other one after a high-fat breakfast.
View complete article: PDF  |  Full-text

Pharmacokinetics of a 1,000 mg Disintegrating Aspirin Tablet Formulation

Migraine is a global disorder and considerably affecting people`s quality of life. Treatments include nonsteroidal anti-inflammatory drugs-containing medicinal products among whom acetylsalicylic acid-containing Aspirin® has been proven effectively to relief migraine headache. Early treatment is recommended for patients with migraine attacks.
View complete article: PDF  |  Full-text

Bioequivalence between two Prolonged Release Tablets of Desvenlafaxine Succinate in Healthy Subjects under Fasting and Fed Conditions

Bioavailability in different formulations of desvenlafaxine100 mg prolonged-release tablets was compared in two bioequivalence studies, one under fasting conditions and the other after a standard breakfast. Both studies were a single dose, randomized, open-label, two-period crossover, with Brazilian male and female healthy subjects. Blood samples were taken during 48 h and plasmatic concentrations were determined using a validated UPLC-MS/MS method.
View complete article: PDF  |  Full-text

Orally Disintegrating Tablets: A Short Review

This article summarizes the advantages of orally disintegrating tablets (ODTs) as well as critical issues during evaluation of ODTs such as bioequivalence and challenges and limitations of ODTs and finally present and the future of ODTs. ODTs have received everincreasing demand and the field has become a rapidly growing area in the pharmaceutical industry.
View complete article: PDF  |  Full-text

Evaluation of Luffa Aegyptica Mill Powder: A Novel Superdisintegrant in Delayed Release Tablets

The current research in the field of drug delivery by which pulsatile release can be achieved has been intensified. The objective of the present study was to evaluate Luffa aegyptica mill powder as a novel superdisintegrant in the development of pulsatile drug delivery system (PDDS).
View complete article: PDF  |  Full-text


Editorial Board Members Related to tablet

ALAA EL-DEEN BAKRY YASSIN

Associate Professor
Department of Pharmaceutical Sciences
King Saud bin Abdulaziz University for Health Sciences
Saudi Arabia

NORMA RANGEL

Professor Research
Division of Graduate Studies and Research
Institute of Technology Aguascalientes (ITA)
Technological Institute of Aguascalientes (ITA)
Mexico

KETAN VINODLAL SHAH

Associate Professor
School of Pharmacy
RK University
India

Khalid M. El-Say

Associate professor
Department of Pharmaceutics and Industrial pharmacy
King Abdulaziz University
Saudi Arabia

TIMUCIN UGURLU

Associate Professor
Department of Pharmaceutical Technology
Marmara University
Turkey
Submit Manuscript


Open Access Journals

View All Journals